within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC05_Gemcitabine;

model Gemcitabine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 2.3777777777777777e-05,
    adminDuration = 600,
    adminMass = 1000 / 1000000,
    adminCount = 1,
    Vd = 0.0502,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.0343,
    k12 = 1.911111111111111e-05,
    k21 = 1.911111111111111e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Gemcitabine</td></tr><tr><td>ATC code:</td><td>L01BC05</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>1000</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>50.2</td><td>L</td></tr>
    <tr><td>clearance:</td><td>85.6</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Gemcitabine is a nucleoside analog used as an antineoplastic (anticancer) agent. It is approved and widely used for treatment of various carcinomas, including pancreatic cancer, non-small cell lung cancer, bladder cancer, and breast cancer. It works primarily by inhibiting DNA synthesis, leading to cell death.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for adult cancer patients (both sexes), typically aged 18-80 years, receiving intravenous infusion of gemcitabine. No major differences were observed based on sex or cancer type.</p><h4>References</h4><ol><li><p>Sugiyama, E, et al., &amp; Sawada, J (2010). Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms. <i>Clinical pharmacokinetics</i> 49(8) 549–558. DOI:<a href=\"https://doi.org/10.2165/11532970-000000000-00000\">10.2165/11532970-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20608756/\">https://pubmed.ncbi.nlm.nih.gov/20608756</a></p></li><li><p>Boosman, RJ, et al., &amp; Huitema, ADR (2022). Is age just a number? A population pharmacokinetic study of gemcitabine. <i>Cancer chemotherapy and pharmacology</i> 89(5) 697–705. DOI:<a href=\"https://doi.org/10.1007/s00280-022-04431-5\">10.1007/s00280-022-04431-5</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35426526/\">https://pubmed.ncbi.nlm.nih.gov/35426526</a></p></li><li><p>Jiang, X, et al., &amp; McLachlan, AJ (2008). Population pharmacokinetics of gemcitabine and its metabolite in patients with cancer: effect of oxaliplatin and infusion rate. <i>British journal of clinical pharmacology</i> 65(3) 326–333. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2007.03040.x\">10.1111/j.1365-2125.2007.03040.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17961191/\">https://pubmed.ncbi.nlm.nih.gov/17961191</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01BC05 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Gemcitabine;
